Valdoxan
(agomelatine)ApprovedSmall molecule
NovartisAgomelatine is used to treat depression by helping to restore normal sleep-wake cycles and improve mood. It works differently than many other antidepressants by acting on melatonin receptors in the brain.[2] Valdoxan is currently approved and in use across 6 indications[4].[1]
Valdoxan is one of 212 small molecule programs targeting Depressive Disorder. It is currently in Approved.
6
Indications
19
Total Trials
1
Active Trials
211
Competitors
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Valdoxan
NovartisApproved
Celexa
AbbViePreclinical
Resotran
TakedaPreclinical
Inapsine
Alnylam PharmaceuticalsPreclinical
Ibrance
PfizerPreclinical
Persantine
Boehringer IngelheimPreclinical
Permax
VValeant Pharmaceuticals
Preclinical
Luvox
SSolvay Pharmaceuticals
Preclinical
Catapres
Boehringer IngelheimPreclinical
Compazine
GGlaxo Dba Glaxosmithkline
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Major Depressive Disorder8 trials
Show 5 more trials
Schizophrenia2 trials
Double-blind1 trial
A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine
Completed·—·Phase 4·NCT04589143·137 enrolled
Adolescent1 trial
6 more indications
Depressed1 trial
Major Depression1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Valdoxan drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for agomelatine. EMBL-EBI & Wellcome Sanger Institute.
- [5]